Base de dados : MEDLINE
Pesquisa : C17.800.862.945 [Categoria DeCS]
Referências encontradas : 9379 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 938 ir para página                         

  1 / 9379 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214791
[Au] Autor:Ahn MJ; Yu JE; Jeong J; Sim DW; Koh YI
[Ad] Endereço:Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
[Ti] Título:A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.
[So] Source:Yonsei Med J;59(1):154-157, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:Chronic urticaria may often be associated with interleukin (IL)-1-mediated autoinflammatory disease, which should be suspected if systemic inflammation signs are present. Here, we report a case of Schnitzler's syndrome without monoclonal gammopathy treated successfully with the IL-1 receptor antagonist anakinra. A 69-year-old man suffered from a pruritic urticarial rash for 12 years. It became aggravated episodically and was accompanied by high fever, arthralgia, leukocytosis, and an elevated C-reactive protein and erythrocyte sedimentation rate. The episodes each lasted for over one week. Neutrophilic and eosinophilic inflammation was found on skin biopsy. However, serum and urine electrophoresis showed no evidence of monoclonal gammopathy. The cutaneous lesions were unresponsive to various kinds of anti-histamines, systemic glucocorticoids, colchicine, cyclosporine, dapsone, and methotrexate, which were administered over a span of 3 years immediately preceding successful treatment. A dramatic response, however, was observed after a daily administration of anakinra. This observation suggests that the correct diagnosis of this case is Schnitzler's syndrome without monoclonal gammopathy. For an adult patient with refractory chronic urticaria and systemic inflammation, Schnitzler's syndrome could be considered as a possible differential diagnosis. Although the typical form of Schnitzler's syndrome exhibits the presence of monoclonal gammopathy as a diagnostic criterion, monoclonal gammopathy may be absent in an atypical form. In such a situation, an IL-1 antagonist should be effective for the management of chronic urticaria.
[Mh] Termos MeSH primário: Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico
Paraproteinemias/complicações
Síndrome de Schnitzler/tratamento farmacológico
Urticária/complicações
[Mh] Termos MeSH secundário: Idoso
Sedimentação Sanguínea
Proteína C-Reativa/metabolismo
Doença Crônica
Seres Humanos
Leucócitos/metabolismo
Masculino
Síndrome de Schnitzler/sangue
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Interleukin 1 Receptor Antagonist Protein); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.154


  2 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406049
[Au] Autor:Salim SA; Yousuf T; Patel A; Fülöp T; Agarwal M
[Ad] Endereço:Department of Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
[Ti] Título:Hypocomplementemic Urticarial Vasculitis Syndrome With Crescentic Glomerulonephritis.
[So] Source:Am J Med Sci;355(2):195-200, 2018 Feb.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare autoimmune disease characterized by multiple organ system involvement, including renal disease, with low complement levels. We report the case of a 31-year-old woman who presented with nonspecific symptoms including fatigue, diarrhea, macular rash and abdominal pain with acute renal failure leading to end-stage kidney disease. Laboratory results showed hematuria, nephrotic range proteinuria, worsening creatinine and low C1q levels. Left kidney biopsy showed proliferative glomerulonephritis with crescent formation. She was treated with 6 months of intravenous cyclophosphamide, followed by 2 doses of intravenous rituximab (1g each), thereafter maintained on mycophenolate mofetil and glucocorticoid-based therapy. She experienced a full recovery of renal function after 12 months of dialysis dependence. Hypocomplementemic urticarial vasculitis syndrome with crescentic glomerulonephritis is a rare disease with only 5 other reported cases in literature. In our case, we document a delayed but excellent renal recovery during a 2-year follow-up.
[Mh] Termos MeSH primário: Ciclofosfamida/administração & dosagem
Glomerulonefrite Membranoproliferativa
Ácido Micofenólico/administração & dosagem
Rituximab/administração & dosagem
Urticária
Vasculite
[Mh] Termos MeSH secundário: Adulto
Complemento C1q/metabolismo
Feminino
Glomerulonefrite Membranoproliferativa/complicações
Glomerulonefrite Membranoproliferativa/tratamento farmacológico
Glomerulonefrite Membranoproliferativa/metabolismo
Glomerulonefrite Membranoproliferativa/patologia
Hematúria/complicações
Hematúria/tratamento farmacológico
Hematúria/metabolismo
Hematúria/patologia
Seres Humanos
Falência Renal Crônica/complicações
Falência Renal Crônica/tratamento farmacológico
Falência Renal Crônica/metabolismo
Falência Renal Crônica/patologia
Proteinúria/complicações
Proteinúria/tratamento farmacológico
Proteinúria/metabolismo
Proteinúria/patologia
Síndrome
Urticária/complicações
Urticária/tratamento farmacológico
Urticária/metabolismo
Urticária/patologia
Vasculite/complicações
Vasculite/tratamento farmacológico
Vasculite/metabolismo
Vasculite/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
4F4X42SYQ6 (Rituximab); 80295-33-6 (Complement C1q); 8N3DW7272P (Cyclophosphamide); HU9DX48N0T (Mycophenolic Acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  3 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254299
[Au] Autor:Kasperska-Zajac A; Grzanka A; Damasiewicz-Bodzek A; Bieniek K; Skrzypulec-Frankel A; Stencel-Gabriel K; Sikora-Zydek A
[Ad] Endereço:Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland.
[Ti] Título:Elevated plasma il-8 concentration is related to severity of systemic inflammation in chronic spontaneous urticaria.
[So] Source:J Biol Regul Homeost Agents;31(4):957-961, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Chronic spontaneous urticaria (CSU) is associated with activation of acute phase response. Questions arise regarding its association with other inflammatory mediators. To determine plasma IL-8 concentration in CSU patients and its association with C-reactive protein (CRP) concentration, a nonspecific inflammatory marker of the disease activity, concentrations of plasma IL-8 and serum CRP were measured in CSU patients and compared with healthy controls. IL-8 and CRP concentrations were significantly higher in CSU patients as compared with the healthy subjects. In addition, there were significant differences in IL-8 and CRP concentrations between CSU patients with moderate-severe symptoms and the healthy subjects. Plasma IL-8 and serum CRP concentrations showed a significant correlation with urticaria activity score (UAS). Additionally, a significant positive correlation was observed between IL-8 and CRP concentrations. Up-regulations of IL-8 and its association with the marker of clinical and inflammatory activity suggest a role of this cytokine in the pathogenesis of CSU.
[Mh] Termos MeSH primário: Proteína C-Reativa/metabolismo
Interleucina-8/sangue
Urticária/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Estudos de Casos e Controles
Doença Crônica
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Urticária/sangue
Urticária/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Interleukin-8); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  4 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29186259
[Au] Autor:Wang SH; Tang SE; Li YH; Wei KY; Chang CY
[Ad] Endereço:Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center - Taipei, Taiwan, Republic of China.
[Ti] Título:Pneumocystis jirovecii pneumonia induced by low-dose methotrexate in a patient with chronic urticaria.
[So] Source:An Bras Dermatol;92(3):401-403, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Methotrexate has immunosuppressive effects and is administered for refractory chronic urticaria. We present a case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria managed by low-dose weekly methotrexate treatment (total cumulative dose 195mg). Our study highlights the importance of providing prompt diagnosis and treatment of Pneumocystis jirovecii pneumonia in patients with chronic urticaria under methotrexate therapy.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/efeitos adversos
Metotrexato/efeitos adversos
Pneumocystis carinii
Pneumonia por Pneumocystis/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Doença Crônica
Fármacos Dermatológicos/administração & dosagem
Feminino
Seres Humanos
Metotrexato/administração & dosagem
Pneumonia por Pneumocystis/diagnóstico por imagem
Tomografia Computadorizada por Raios X
Urticária/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Dermatologic Agents); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  5 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779432
[Au] Autor:Sharma VK; Gupta V; Pathak M; Ramam M
[Ad] Endereço:a Department of Dermatology and Venereology , All India Institute of Medical Sciences , New Delhi , India.
[Ti] Título:An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose.
[So] Source:J Dermatolog Treat;28(6):539-543, 2017 Sep.
[Is] ISSN:1471-1753
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The EAACI/GA LEN/EDF/WAO recommendation of increasing antihistamines' dose up to four times in urticaria not adequately controlled with the standard dose is largely based on expert opinion. The objective of this study is to test the current urticaria guidelines of up-dosing antihistamines as second-line treatment. METHODS: This was an open-label study conducted prospectively on 113 patients with chronic spontaneous urticaria. All patients were treated with sequentially increasing doses of levocetrizine (5 mg, 10 mg, 15 mg and 20 mg/day) every week till the patients became completely asymptomatic or dose of 20 mg/day reached. Urticaria Activity Score (UAS)-7, urticaria-related quality-of-life (CU-Q2oL) and patients' global assessment were used to assess treatment response. RESULTS: Twenty-one (18.58%) patients became asymptomatic with levocetirizine 5 mg/day, while 50 required higher doses of levocetirizine for complete control: 29/92 (31.52%), 6/63 (9.52%) and 15/57 (26.31%) with 10 mg, 15 mg and 20 mg/day, respectively. The percentage of patients experiencing >75% improvement increased with increasing doses of levocetirizine: 26.54%, 53.98%, 60.17% and 69.91% with 5 mg, 10 mg, 15 mg and 20 mg/day, respectively. Sequential up-dosing of levocetirizine produced a progressive improvement in both urticaria control (UAS-7) and quality-of-life (CU-Q2oL) without significantly increasing somnolence. CONCLUSIONS: Our results support the current recommendations of increasing antihistamines up to four times the standard dose in patients who fail the first-line treatment.
[Mh] Termos MeSH primário: Cetirizina/uso terapêutico
Antagonistas dos Receptores Histamínicos H1 não Sedativos/uso terapêutico
Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Cetirizina/efeitos adversos
Doença Crônica
Distúrbios do Sono por Sonolência Excessiva/etiologia
Relação Dose-Resposta a Droga
Feminino
Antagonistas dos Receptores Histamínicos H1 não Sedativos/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Qualidade de Vida
Índice de Gravidade de Doença
Resultado do Tratamento
Urticária/patologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H1 Antagonists, Non-Sedating); 6U5EA9RT2O (levocetirizine); YO7261ME24 (Cetirizine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1080/09546634.2016.1246705


  6 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29284253
[Au] Autor:Spiewak R; Góra-Florek A; Horoch A; Jarosz MJ; Dorynska A; Golec M; Dutkiewicz J
[Ad] Endereço:Department of Experimental Dermatology and Cosmetology, Jagiellonian University Medical College, Krakow, Poland. spiewak.eu@gmail.com.
[Ti] Título:Risk factors for work-related eczema and urticaria among vocational students of agriculture.
[So] Source:Ann Agric Environ Med;24(4):716-721, 2017 Dec 23.
[Is] ISSN:1898-2263
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION AND OBJECTIVE: Farmers are at high risk of occupational skin diseases which may start already during vocational training. This study was aimed at identification of risk factors for work-related skin diseases among vocational students of agriculture. MATERIAL AND METHODS: The study involved 440 students (245 males, 195 females aged 17-21 years) in 11 vocational schools which were at least 100 km from each other. The protocol included a physician-managed questionnaire and medical examination, skin prick tests, patch tests, total IgE and Phadiatop. Logistic regression model was used for the identification of relevant risk factors. RESULTS: Work-related dermatoses were diagnosed in 29 study participants (6.6%, 95%CI: 4.3-8.9%): eczema in 22, urticaria in 14, and co-existence of both in 7 students. Significant risk factors for work-related eczema were: history of respiratory allergy (OR=10.10; p<0.001), history of eczema (itchy rash) provoked by wet work and detergents before entering the school (OR=5.85; p<0.001), as well as history of contact dermatitis to metals, rubber or cosmetics prior to inscription (OR=2.84; p=0.016), and family history of any skin disease (OR=2.99; p=0.013). Significant risk factors for work-related urticaria were: history of allergic rhinitis and asthma prior to inscription (OR=7.29; p=0.006), positive skin prick tests to work place allergens (OR=4.65; p=0.002) and to environmental allergens (OR=3.79; p=0.009), and positive Phadiatop test (OR=3.61; p=0.013). CONCLUSIONS: Work-related skin diseases are common among vocational students of agriculture. Atopy, past history of asthma, allergic rhinitis, and eczema (either atopic, allergic or irritant) are relevant risk factors for work-related eczema and urticaria in young farmers, along with family history of any skin disease. Positive skin prick tests seem relevant, especially in the case of urticaria. Asking simple, aimed questions during health checks while enrolling students into agricultural schools would suffice to identify students at risk for work-related eczema and urticaria, giving them the chance for selecting a safer profession, and hopefully avoiding an occupational disease in the future.
[Mh] Termos MeSH primário: Doenças dos Trabalhadores Agrícolas/epidemiologia
Eczema/epidemiologia
Urticária/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Doenças dos Trabalhadores Agrícolas/diagnóstico
Agricultura
Eczema/diagnóstico
Fazendeiros/estatística & dados numéricos
Feminino
Seres Humanos
Masculino
Fatores de Risco
Testes Cutâneos
Estudantes/estatística & dados numéricos
Urticária/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE


  7 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452145
[Au] Autor:Rutkowski K; Grattan CEH
[Ad] Endereço:Urticaria Clinic, St John's Institute of Dermatology, London, UK.
[Ti] Título:How to manage chronic urticaria 'beyond' guidelines: a practical algorithm.
[So] Source:Clin Exp Allergy;47(6):710-718, 2017 Jun.
[Is] ISSN:1365-2222
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic urticaria (CU) is a disease characterized by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders. Our algorithm and a summary of the evidence to support its principles offers guidance and a more systematic targeted approach to using a range of 'off-label' agents for specific phenotypes of CU. It will be of use when guideline-recommended mast cell mediator antagonists fail to control symptoms and/or using omalizumab is ineffective, not practical or unfunded.
[Mh] Termos MeSH primário: Algoritmos
Antialérgicos/uso terapêutico
Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Crônica/tratamento farmacológico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Allergic Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/cea.12944


  8 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29052900
[Au] Autor:Asero R
[Ad] Endereço:Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
[Ti] Título:Towards a better categorization of patients with chronic urticaria.
[So] Source:Br J Dermatol;177(4):903-904, 2017 10.
[Is] ISSN:1365-2133
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença Crônica
Urticária
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171021
[St] Status:MEDLINE
[do] DOI:10.1111/bjd.15806


  9 / 9379 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28697833
[Au] Autor:Tang N; Mao MY; Zhai R; Chen X; Zhang JL; Zhu W; Li J
[Ad] Endereço:Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China. xylijie@medmail.com.cn.
[Ti] Título:[Clinical characteristics of urticaria in children versus adults].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(7):790-795, 2017 Jul.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To study the clinical characteristics of urticaria in children versus adults, and to provide reference for the etiological analysis, disease evaluation, and treatment of urticaria in children. METHODS: The clinical data of 2 411 patients with urticaria who visited the Department of Dermatology at Xiangya Hospital of Central South University from January 2013 to May 2017 were collected to study their socio-demographic characteristics. The clinical characteristics of urticaria were compared between the 68 children and 672 adults of the 740 patients with complete follow-up data. RESULTS: Among the 411 pediatric patients, 314 (76.4%) had acute urticaria; among the 2 000 adult patients, 896 (44.8%) had chronic spontaneous urticaria. The causes of acute urticaria in children included infection (41%, 16/39). The accompanying symptoms of acute urticaria in children mainly included abdominal pain and diarrhea (44%, 17/39), while those in adults mainly included chest distress and shortness of breath (32%, 11/34). Compared with the adult patients, the pediatric patients had significantly lower chronic urticaria activity scores before and after treatment (P<0.05), a significantly higher rate of response to second-generation antihistamines (82.1% vs 62.2%; P<0.05), and a significantly higher proportion of individuals with a personal and family history of urticaria (P<0.05). CONCLUSIONS: Acute urticaria is more commonly seen than chronic urticaria in children with urticaria, and the main accompanying symptoms are abdominal pain and diarrhea, which are different from adults with urticaria. Chronic urticaria has a better treatment outcome in children than in adults. The most frequently seen cause of acute urticaria is infection in children. Atopic children may be susceptible to urticaria.
[Mh] Termos MeSH primário: Urticária/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Meia-Idade
Urticária/etiologia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  10 / 9379 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28685545
[Au] Autor:Grzanka A; Damasiewicz-Bodzek A; Szumska M; Kasperska-Zajac A
[Ad] Endereço:Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland.
[Ti] Título:Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
[So] Source:J Biol Regul Homeost Agents;31(2):407-411, 2017 Apr-Jun.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Little is known about the role of the kallikrein-kinin system in chronic spontaneous urticaria (CSU). Kallikrein 5 (KLK5), a trypsin-like enzyme, is the most abundant in the skin and plays a role in itching and inflammatory reaction. In this study, we determined plasma KLK5 concentration, and its associations with acute phase response in CSU patients. Concentrations of KLK5 in plasma and CRP in serum were measured in patients with CSU of varying severity and in the healthy subjects. Plasma KLK5 concentrations were significantly lower in CSU (all) and moderate-severe CSU patients, as compared with the controls. There were no significant differences in KLK5 concentration in mild CSU patients as compared with the healthy subjects and moderate-severe CSU patients. No correlation was observed between KLK5 and CRP concentrations in the patients. It may be considered that circulating kallikrein 5 is down-regulated in CSU patients, however its potential role and the possible underlying mechanism are unknown.
[Mh] Termos MeSH primário: Calicreínas/sangue
Urticária/sangue
[Mh] Termos MeSH secundário: Adulto
Proteína C-Reativa/metabolismo
Doença Crônica
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
9007-41-4 (C-Reactive Protein); EC 3.4.21.- (KLK5 protein, human); EC 3.4.21.- (Kallikreins)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE



página 1 de 938 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde